11630 SW 97 Street, Miami, Florida 33176, US
Advertising Driven Press Release Distribution
Advertising Driven Press Release Distribution
DelveInsight’s ‘Glioblastoma Multiforme (GBM) Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Glioblastoma Multiforme (GBM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
The epidemiology report gives a thorough understanding of the disease symptoms and causes, as well as the risk factors, diagnosis, pathophysiology associated with the disease, and treatment guidelines for Glioblastoma Multiforme (GBM) in 7MM. The report provides epidemiology of GBM segmented by total diagnosed incident cases, age, gender, type-specific diagnosed incident cases, diagnosed incident population-based on primary site of GBM, and diagnosed incident population based on the histologic classification of GBM.
Request for Sample @ Glioblastoma Multiforme (GBM) Epidemiology Forecast
Key Highlights of the Glioblastoma Multiforme (GBM) Epidemiology Report
Visit to get a more detailed insight into the patient pool @ Glioblastoma Multiforme (GBM) Epidemiology and Patient Population
Glioblastoma Multiforme (GBM) Disease Overview
Glioblastoma, also known as glioblastoma multiforme, is the most frequently occurring type of primary tumor that affects the brain or spinal cord. According to the American Association of Neurological Surgeons, GBM has an incidence of 2–3 per 100,000 adults per year and accounts for 52% of all primary brain tumors. Overall, GBM accounts for about 17% of all tumors of the brain (primary and metastatic). These tumors tend to occur in adults between the ages of 45 and 70 and are more common in men than women.
It is a quite aggressive tumor and mostly affects adults. As of now, there is no cure for Glioblastoma. Over the past few years, innovative diagnostic strategies and new therapies have been developed. However, the available treatment options only help to ease the symptoms. It is observed that the median survival time for patients with GBM is only 14.6 months.
Glioblastoma Multiforme (GBM) Epidemiology Segmentation
Dive deeper to know more @ Glioblastoma Multiforme (GBM) Epidemiology Analysis
Scope of the Report
Check out for more @ Glioblastoma Multiforme (GBM) Epidemiology
Table of Contents
| 1 | Key Insights |
| 2 | Glioblastoma Multiforme (GBM): Overview at a Glance |
| 3 | Executive Summary of Glioblastoma Multiforme (GBM) |
| 4 | Disease Background and Overview: Glioblastoma Multiforme (GBM) |
| 5 | Glioblastoma Multiforme (GBM): Epidemiology and Patient Population |
| 6 | Glioblastoma Multiforme (GBM): Country Wise-Epidemiology |
| 7 | Appendix |
| 8 | DelveInsight Capabilities |
| 9 | Disclaimer |
| 10 | About DelveInsight |
*The table of contents is not exhaustive; will be provided in the final report
Key Highlight of the Reports
Got queries? Reach out for more information @ Glioblastoma Multiforme (GBM) Epidemiology Report
Related Reports
Glioblastoma multiforme (GBM) Market Insight
DelveInsight’s “Glioblastoma multiforme (GBM) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Glioblastoma multiforme (GBM) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Glioblastoma multiforme (GBM) Pipeline Insights
Glioblastoma multiforme (GBM) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Glioblastoma multiforme (GBM) market.
Anti-hypertension Market Insight
DelveInsight’s “Anti-hypertension Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Anti-hypertension market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Amebiasis Market Insight
DelveInsight’s “Amebiasis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Amebiasis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Bevacizumab Biosimilars Insight
DelveInsight’s, “Bevacizumab Biosimilar Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ulcerative Colitis (UC) Market Insight
DelveInsight’s “Ulcerative Colitis (UC) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Ulcerative Colitis (UC) market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Traumatic Brain Injury Market Insight
DelveInsight’s “Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Traumatic Brain Injury market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Latest Healthcare Blog
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
For exclusive content regarding the latest trends in the world of Press Release distribution.
